© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
May 7th 2021, 9:00pm
By Colleen Moretti
Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.
May 7th 2021, 6:00pm
By Mike Hennessy, Sr.
Luckily, obtaining a second opinion has become easier with advances in telehealth and other virtual technologies, which allow patients to share their medical records and test results with physicians and pathologists to potentially improve treatment plans.
May 7th 2021, 4:00pm
By Robin Zimmerman
A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.
May 7th 2021, 3:00pm
By Jamie Cesanek
From a 114-year-old cancer survivor breaking records to an operating room nurse giving birth to a cancer survivor’s baby, here’s what’s happening in the cancer landscape this week.
May 7th 2021, 1:00pm
Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.
May 6th 2021, 9:00pm
Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.
May 6th 2021, 6:00pm
By Ryan McDonald
Members of an FDA committee voted in favor of Tecentriq plus Abraxane keeping its accelerated approval for the treatment of adults with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.
May 6th 2021, 4:00pm
By Kelly Irvin
“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”
May 6th 2021, 3:00pm
In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.
May 6th 2021, 1:52pm
The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.
May 6th 2021, 1:00pm
Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.
May 5th 2021, 9:00pm
FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.
May 5th 2021, 6:58pm
By Darlene Dobkowski, MA
Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.
May 5th 2021, 6:00pm
Women who receive a breast cancer diagnosis were more likely to develop unhealthy behaviors one and two years after diagnosis, even if they were considered healthy at time of diagnosis.
May 5th 2021, 4:00pm
By Jane Biehl Ph.D.
A cancer survivor recalls how a book quote about a blizzard became a metaphor for her own experiences with cancer.
This Month in Kidney Cancer Research from the KCA
Meet Maia and Manju, Clinical Trial Champions
Here Today Because of a Whipple Procedure
Got a Bladder Cancer Question? Ask the Experts